Search
Displaying 331–340 of 526 for “Retinitis pigmentosa”
-
MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial
Research NewsThe MeiraGTx gene therapy involves injection of healthy copies of RPGR underneath the retina. The RPGR copies are contained in a human-engineered virus — known as an adeno-associated virus or AAV — designed to readily penetrate retinal cells to deliver the therapeutic genetic cargo.
-
Research News
The partnership will help companies and researchers quickly obtain and implement high-quality vectors for their retinal gene-therapy development efforts.
-
SparingVision Formed to Advance Sight-Saving Protein for RP
Research NewsSparingVision received a €300,000 award known as the Honor Prize from the French Ministry of Research. The award is given to new, innovative companies in France competing in a national contest.
-
Forty-Four High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit
Research NewsIn its fourth year, the meeting is becoming the world’s most comprehensive overview of the promising research underway for emerging IRD treatments.
-
jCyte Stem-Cell Therapy Moves into Phase IIb Clinical Trial for RP
Research NewsBased on lab studies, researchers believe the treatment can preserve and potentially rescue the patient’s existing photoreceptors, thereby saving and possibly restoring vision.
-
FFB-CRI Launching Natural History Study for People with USH2A Mutations
Research NewsThe study — known as RUSH2A (“R” stands for “rate of progression”) — is beginning in spring 2017 and will take place at about 20 clinical sites around the world. RUSH2A investigators will use a variety of technologies to monitor changes in vision and retinal structure to document and analyze disease progression.
-
First Patient Treated in XLRP Gene Therapy Clinical Trial
Research NewsThe Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.
-
Unregulated Stem-Cell Therapy Causes Severe Vision Loss for Three Florida Women
Research News“…participation in a study for an emerging therapy that is not regulated by the FDA or another well-recognized regulatory agency like the European Medicines Agency in Europe, is fraught with dangers and can lead to unexpected serious consequences.”
-
AGTC Leverages Funding from the Foundation to Move Promising Treatments into Clinical Trials
Research NewsCompany Builds on FFB’s Initial Investment to Garner $265 Million in Therapy Development Funding
-
Foundation Investing in Drug to Slow Many Forms of RP
Research NewsThe Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has announced an investment of up to $7.5 million to advance the potential therapy into and through a Phase II clinical trial.
